検索結果

お知らせ | 千寿製薬株式会社

2025年12月22日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel sub...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

ENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical trials. This information on this...

お知らせ | 千寿製薬株式会社

December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

ENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical trials. This information on this...

f Phase III clinical trials in Japan, which consisted of the comparative (placebo-controlled) trial and the long-term administration trial. During the comparative trial, the primary efficacy endpoints...